S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
NOTICE: Your retirement is in immediate danger (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
NOTICE: Your retirement is in immediate danger (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The single greatest medical breakthrough of all time? (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
NOTICE: Your retirement is in immediate danger (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
NOTICE: Your retirement is in immediate danger (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The single greatest medical breakthrough of all time? (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
NOTICE: Your retirement is in immediate danger (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
NOTICE: Your retirement is in immediate danger (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The single greatest medical breakthrough of all time? (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
NOTICE: Your retirement is in immediate danger (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
NOTICE: Your retirement is in immediate danger (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The single greatest medical breakthrough of all time? (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
NASDAQ:IDXX

IDEXX Laboratories (IDXX) Stock Forecast, Price & News

$465.28
-5.55 (-1.18%)
(As of 06/5/2023 ET)
Compare
Today's Range
$459.76
$469.99
50-Day Range
$458.06
$503.61
52-Week Range
$317.06
$515.79
Volume
416,773 shs
Average Volume
361,824 shs
Market Capitalization
$38.57 billion
P/E Ratio
55.99
Dividend Yield
N/A
Price Target
$527.86

IDEXX Laboratories MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
13.4% Upside
$527.86 Price Target
Short Interest
Bearish
2.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.09
Upright™ Environmental Score
News Sentiment
0.34mentions of IDEXX Laboratories in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$6.40 M Sold Last Quarter
Proj. Earnings Growth
15.34%
From $9.65 to $11.13 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

198th out of 985 stocks

Diagnostic Substances Industry

5th out of 15 stocks


IDXX stock logo

About IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, a

Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Stock News Headlines

"The $51 Billion Laser Revolution"
See how a new contract with the Pentagon could spark a 2,476% sales surge for a small laser firm >>>
Here’s Why IDEXX Laboratories (IDXX) Rose in Q1
Idexx Laboratories (NASDAQ: IDXX)
"The $51 Billion Laser Revolution"
See how a new contract with the Pentagon could spark a 2,476% sales surge for a small laser firm >>>
IDEXX Laboratories' Debt Overview
Idexx Laboratories (IDXX) Gets a Buy from Goldman Sachs
Q1 2023 IDEXX Laboratories Inc Earnings Call
See More Headlines

IDXX Price History

IDXX Company Calendar

Last Earnings
2/06/2023
Today
6/05/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
10,780
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$527.86
High Stock Price Forecast
$600.00
Low Stock Price Forecast
$415.00
Forecasted Upside/Downside
+13.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$679.09 million
Pretax Margin
25.83%

Debt

Sales & Book Value

Annual Sales
$3.37 billion
Cash Flow
$9.44 per share
Book Value
$7.35 per share

Miscellaneous

Free Float
81,151,000
Market Cap
$38.57 billion
Optionable
Optionable
Beta
1.19

Social Links


Key Executives

  • Jonathan J. MazelskyJonathan J. Mazelsky
    President, Chief Executive Officer & Director
  • John Hart
    Senior Vice President-Global Operations
  • Brian Patrick McKeon
    Chief Financial Officer, Treasurer & Executive VP
  • Ken Grady
    Chief Information Officer & Senior VP
  • Murthy Yerramilli
    Senior Vice President-Research & Development













IDXX Stock - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IDXX shares.
View IDXX analyst ratings
or view top-rated stocks.

What is IDEXX Laboratories' stock price forecast for 2023?

7 brokers have issued 1 year price targets for IDEXX Laboratories' shares. Their IDXX share price forecasts range from $415.00 to $600.00. On average, they expect the company's share price to reach $527.86 in the next year. This suggests a possible upside of 13.4% from the stock's current price.
View analysts price targets for IDXX
or view top-rated stocks among Wall Street analysts.

How have IDXX shares performed in 2023?

IDEXX Laboratories' stock was trading at $407.96 at the start of the year. Since then, IDXX stock has increased by 14.1% and is now trading at $465.28.
View the best growth stocks for 2023 here
.

When is IDEXX Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our IDXX earnings forecast
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings results on Monday, February, 6th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.92 by $0.13. The company earned $828.60 million during the quarter, compared to analyst estimates of $820.91 million. IDEXX Laboratories had a trailing twelve-month return on equity of 117.37% and a net margin of 20.38%. The business's revenue for the quarter was up 3.4% on a year-over-year basis. During the same period last year, the company posted $1.89 EPS.
Read the conference call transcript
.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY23 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share guidance of $9.33-$9.75 for the period, compared to the consensus estimate of $9.63. The company issued revenue guidance of $3.619-$3.70 billion, compared to the consensus revenue estimate of $3.66 billion.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (10.49%), State Street Corp (4.43%), Geode Capital Management LLC (2.35%), Franklin Resources Inc. (1.63%), Blair William & Co. IL (1.46%) and Brown Advisory Inc. (1.38%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends
.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $465.28.

How much money does IDEXX Laboratories make?

IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $38.57 billion and generates $3.37 billion in revenue each year. The company earns $679.09 million in net income (profit) each year or $8.31 on an earnings per share basis.

How many employees does IDEXX Laboratories have?

The company employs 10,780 workers across the globe.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346.

This page (NASDAQ:IDXX) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -